{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/616d927ae607a20013d1c9d9?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ebe8cc563e3d811bbd2c9d8/1589546617002-fe8127d1b39ab8ac94a64885bbfaa0ae.jpeg?height=200","description":"<p>During the 18th International&nbsp;Myeloma&nbsp;Workshop, the Multiple&nbsp;Myeloma&nbsp;Hub spoke with Michel&nbsp;Delforge,&nbsp;UCLouvain, Louvain-la-Neuve, BE and&nbsp;Noopur&nbsp;Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel&nbsp;immunotherapies: Prevention, treatment, and impact on&nbsp;the quality of&nbsp;life of patients with multiple&nbsp;myeloma.</p><p><br></p><p>Raje&nbsp;and&nbsp;Delforge&nbsp;discuss&nbsp;the management of&nbsp;infections with novel&nbsp;immunotherapies, including: monoclonal antibodies, antivirals, risk of infection, intravenous&nbsp;immunoglobulin,&nbsp;and&nbsp;the impact of COVID-19. This podcast closely links to our latest editorial theme,&nbsp;in which&nbsp;the Multiple&nbsp;Myeloma&nbsp;Hub explores how to manage adverse events from novel agents, with our first article examining&nbsp;proteasome&nbsp;inhibitors and cardiovascular events.</p>","author_name":"Scientific Education Support"}